SoniVie

Pulmonary Hypertension Denervation Treatment

Health Tech & Life Sciences
Acquired by Boston Scientific on Mar, 2025

Company Overview

Snapshot

Founded in August 2014, SoniVie operates with 1–10 employees. The company has raised $73.26M across 3 funding rounds from 6 investors. In March 2025, SoniVie was acquired by Boston Scientific.

Business overview

SoniVie is a medical device company focused on developing a system for the treatment of pulmonary hypertension (PAH). Its core product, the therapeutic intravascular ultrasound (TIVUS) catheter, is designed to selectively damage nerves associated with disease activity in the pulmonary artery, aiming to slow disease progression. The company serves the healthcare industry, specifically targeting hospitals, doctors, healthcare providers, and clinics with its medical devices and treatments.

Strategic signal

In March 2025, SoniVie was acquired by Boston Scientific. This acquisition signals a significant validation of SoniVie's TIVUS system and its potential impact on the treatment of pulmonary hypertension, indicating a strategic move by a major medical technology company to integrate innovative solutions into its portfolio and expand its market reach in cardiovascular health.

Company Intelligence Q&A

What was the most significant corporate event for SoniVie recently?
In March 2025, SoniVie was acquired by Boston Scientific, marking a major exit for the company.
When did SoniVie receive FDA Breakthrough Device Designation for its TIVUS system for renal artery denervation?
SoniVie received FDA Breakthrough Device Designation for its TIVUS system for renal artery denervation in December 2020.
When did SoniVie receive FDA Breakthrough Device Designation for its TIVUS system for pulmonary arterial hypertension?
SoniVie received FDA Breakthrough Device Designation for its TIVUS system in the treatment of pulmonary arterial hypertension (PAH) in September 2019.
Which investors participated in SoniVie's January 2023 funding round?
In January 2023, SoniVie received funding from investors including lead investor Andera Partners.
When did SoniVie appoint Raymond W. Cohen as Chairman of its Board of Directors?
In November 2024, SoniVie Ltd. appointed veteran medtech executive Raymond W. Cohen as Chairman of its Board of Directors.

External links